key: cord-0823896-6wxwv0r2
authors: Cui, Ning; Zou, Xugong; Xu, Lin
title: Preliminary CT findings of coronavirus disease 2019 (COVID-19)
date: 2020-05-12
journal: Clin Imaging
DOI: 10.1016/j.clinimag.2020.04.042
sha: 914f97b59d2de75993cdad85b151e6c30f3ebc24
doc_id: 823896
cord_uid: 6wxwv0r2

OBJECTIVES: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This paper aims to examine the CT imaging characteristics of COVID-19. METHODS: We evaluated CT images obtained between 10 January 2019 and 16 February 2020 at Taihe Hospital. Scans were conducted 2–6 times per patient and the re-testing interval was 2–7 days. Ninety-five patients with positive SARS-CoV-2 nucleic acid test results were included in this study and we retrospectively analysed their CT imaging characteristics. RESULTS: Ninety-five patients underwent 2–3 SARS-CoV-2 nucleic acid tests and received a definitive diagnosis of COVID-19. Fifty-three were male and 42 were female, and their mean age was 42 ± 12 years (range: 10 months to 81 years). Sixty-nine patients (72.6%) experienced fever, fatigue, and dry cough, while 15 (15.8%) had poor appetite and fatigue, and 11 (11.6%) had a dry cough and no fever. On CT imaging, early stage patients (n = 53, 55.8%) showed peripheral subpleural ground-glass opacities; these were mainly local patches (22/53, 41.5%), while some lesions were accompanied by interlobular septal thickening. Thirty-four (35.8%) patients were classified in the ‘progression stage’ based on CT imaging; these patients typically showed lesions in multiple lung segments and lobes (21/34，61.8%), and an uneven increase in ground-glass opacity density accompanied by consolidation and grid-like or cord-like shadows(30.5%). Two patients (2.1%) showed a severe presentation on CT. These showed diffuse bilateral lung lesions, mixed ground-glass opacities and consolidation with cord-like interstitial thickening and air bronchograms, entire lung involvement with a “white lung” presentation, and mild pleural effusion. Six patients in remission (6.3%), visible lesion absorption, fibrotic lesions. Based on clinical signs, 71 (74.7%), 22 (23.2%), and 2 (2.1%) patients had mild or moderate, severe, and critical disease, respectively. Within the follow-up period, 93 patients recovered and were discharged, including the 53 early stage patients and 34 progression stage patients. The length of hospitalisation was 7–28 days (mean: 10 ± 3.5 days). On discharge, lesions were significantly reduced in area and had in many cases completely disappeared, while slight pulmonary fibrosis was present in some patients. One severe stage patient was still hospitalised at the end of the follow-up period and the other severe stage patient died. The overall mortality rate was 1.05%. CONCLUSIONS: Understanding the CT imaging characteristics of COVID-19 is important for early lesion detection, determining the nature of lesions, and assessing disease severity.

Coronavirus disease 2019 (COVID- 19) is an acute pneumonia caused by the β-coronavirus ‗severe acute respiratory syndrome coronavirus' (SARS-CoV-2). This virus is enveloped, spherical or oval in shape, polymorphic, and has a diameter of 60-140 nm [1] . Genetically, it is significantly different from SARS-CoV and MERS-CoV.

While COVID-19 patients are the main source of infection, asymptomatic patients can be similarly infectious. The main transmission routes are through respiratory droplets Journal Pre-proof J o u r n a l P r e -p r o o f and close contact; transmission is also possible when individuals are exposed to high concentrations of aerosols in a sealed environment, while faecal-oral transmission remains to be confirmed [2] [3] [4] . The clinical signs of infection include lower respiratory tract disease accompanied by fever, dry cough, and dyspnoea. A positive test for the SARS-CoV-2 nucleic acid is required for definitive diagnosis [5] . However, while the specificity of nucleic acid testing is high, the sensitivity is relatively low and there is an appreciable false negative rate. Diagnosis with chest computed tomography (CT) is more intuitive and faster; chest CT is therefore the main method used for screening and diagnosis [6, 7] . CT scans play an important role in the diagnosis and treatment of lung disease. Based on our experience, the imaging findings in COVID-19 infection are diverse and range from a normal appearance to diffuse pulmonary changes. In this study, we retrospectively analysed CT imaging data from 95 patients with confirmed COVID-19 in our hospital in order to examine the CT characteristics of infection.

In our hospital, 95 patients underwent CT scans and tested positive for SARS-CoV-2 nucleic acid. This study included patients who met one of the following three sets of criteria: 1. History of residence in the region of the epidemic within the last two weeks, apparent pulmonary lesions, and positive SARS-CoV-2 nucleic acid test results; 2. Patients with the above epidemiological history accompanied by fever, sore throat, diarrhoea, and other respiratory and gastrointestinal symptoms, abnormal pulmonary lesions, and positive SARS-CoV-2 nucleic acid test results; 3. Subjects who came into contact with patients with fever without personal protection, and who had a positive SARS-CoV-2 nucleic acid test result, positive first CT scan results, and lung abnormalities on re-examination. The following patients were excluded from analysis: 1. Patients with a medical history supportive of COVID-19 infection but no history of contact with people in the epidemic region or with patients with fever/respiratory symptoms; 2. Patients with respiratory diseases such as tuberculosis, tumours, and other types of pneumonia; 3. Patients with gastrointestinal symptoms Journal Pre-proof J o u r n a l P r e -p r o o f due to a gastrointestinal disorder or lesions leading to loss of appetite; 4. Patients with complicated respiratory and gastrointestinal symptoms resulting from other causes such as trauma, bleeding, or malignancy.

This study included 53 males and 42 females aged from 10 months to 81 years (mean age: 42±12 years). Sixty-nine patients (72.6％) experienced fever, fatigue, and dry cough, while 15 (15.8％) experienced poor appetite and fatigue, and 11 (11.6%) had a dry cough and no fever. Seventy-one (74.7%), 22 (23.2%), and 2 (2.1%) patients developed moderate, severe, and critical disease, respectively. At the time of the first CT scan, 19 (20％), 64 (67.4％), and 12 (12.6％) patients had experienced fever for 1-3, 4-7, and 7-10 days, respectively. Two to six CT scans were conducted; the interval between scans was 2-7 days.

According to the -COVID-19 Imaging Examination and Diagnosis Quality Control Protocol (interim 3rd edition)‖, patients with suspected COVID-19 wore N95 masks or surgical masks during imaging. Before entering the imaging room, their hands were disinfected. The radiology technician wore protective gear, ensured that no other people were present, and stayed within the isolation zone. Patients adopted a supine position and held their breath. The GE HealthOptima660 and LightspeedCT machines were used for chest CT scans. The scan parameters were set as follows: tube voltage 120 kV, tube current 200 mA, slice interval 5 mm, acquisition slice thickness 0.625 mm, scanning duration less than 5 s, standard lung window level 530-430 HU, and window width 1400-1600 HU. The mediastinal window level was 35-40 HU and the window width was 300-350 HU. The scanning range was from the entrance of the thoracic cavity to the posterior costophrenic angle.

After scanning, the image was evaluated to ensure that the examination was successful and the image quality was sufficient for diagnosis. Chest CT re-examinations were carried out every 5-7 days to assess lesion outcomes.

After imaging of suspected COVID-19 patients, personal protective equipment was removed and appropriate disinfection procedures were followed for equipment and Journal Pre-proof J o u r n a l P r e -p r o o f personnel.

Images were interpreted by two senior radiologists experienced in chest radiology. All imaging data were analysed in the absence of clinical or laboratory results. After independent evaluation, any discrepancies were resolved through discussion and negotiation.

Patients with single or multiple local ground-glass opacities (GGOs) in the subpleural region of the lung periphery or along the bronchovascular bundle, as well as air bronchograms and mild septal thickening at adjacent lobes, were included in the early stage imaging presentation group [8] . The progression stage group comprised patients who developed new lesions or an increase in the original lesion area, multiple lobar involvement, an increased density and appearance of consolidations of varying size and degree, a grid-like shadow, -crazy-paving sign‖, -halo sign‖, or -reverse halo sign‖. Patients with diffuse bilateral lung lesions, whole lung involvement and a -white lung‖ presentation, air bronchograms, pleural thickening, and mild pleural effusion were included in the severe stage group.

Moderate: fever and respiratory symptoms; signs of pneumonia on imaging.

Severe: respiratory distress; respiratory rate (RR) ≥30 breaths/min; finger oxygen saturation ≤93% at rest; arterial partial pressure of oxygen (PaO 2 )/fraction of inspired oxygen (FiO 2 ) ≤300 mmHg.

Critical: respiratory failure leading to the requirement for mechanical ventilation;

shock; other organ failure necessitating treatment in the intensive care unit (ICU).

Patients were required to satisfy the following four criteria for discharge: 1. Normal temperature for three days or more; 2. Significant improvement in respiratory symptoms; 3. Significant absorption of exudative lesions observed on lung CT; 4.

J o u r n a l P r e -p r o o f Two consecutive negative results for the SARS-CoV-2 nucleic acid on respiratory samples (with an interval of at least one day between tests).

Quantitative data was expressed as mean ± standard deviation. SPSS software was used for statistical analysis (SPSS, Chicago, IL, USA).

Ninety-five patients with suspected COVID-19 underwent two to three SARS-CoV-2 nucleic acid tests for definitive diagnosis. All patients showed signs of COVID-19 pneumonia on chest imaging during diagnosis. Fifty-three (55.8%) patients were classified as early stage (Figures 1 and 2 ). These cases frequently showed peripheral subpleural ground-glass opacities, which were observed as local patches in 22/53 patients (41.5%). Ground-glass opacities were seen with interlobular septal thickening in 4/53 patients (7.5%). Thirty-four (35.8 ％ ) patients were classified into the progression stage (Figures 3 and 4) ; these patients commonly exhibited lesions in multiple lung segments and lobes (21/34，61.8％), with an uneven increase in ground-glass opacity density accompanied by consolidation and grid-like or cord-like shadows(30％).There were two (2.1%) patients in the severe stage group ( Figure   5 ),these presented with diffuse bilateral lung lesions, mixed ground-glass opacities and consolidation with cord-like interstitial thickening or air bronchograms, entire lung involvement with a -white lung‖ presentation, and a slight pleural effusion.Six patients in remission (6.3%)( Table 1 ). The distribution and severity of lesions on imaging progressed during the course of the disease, and one or multiple imaging presentations could be identified at each stage (Table 2) (Table 3) .

Within the follow-up period, 93 patients recovered and were discharged, including the 53 early stage patients and 34 progression stage patients. The length of hospitalization was 7 to 28 days and the mean length of hospitalization was 10±3.5 days. On discharge, lesions had significantly reduced in area or had completely disappeared, though slight pulmonary fibrosis was present in some patients. One severe stage Journal Pre-proof J o u r n a l P r e -p r o o f patient was still hospitalized at the end of the follow-up period and one severe stage patient died. The overall mortality rate was 1.05%.

The typical clinical presentation of COVID-19 is fever, fatigue, and dry cough; this presentation is consistent with lower respiratory tract infection. Nasal congestion, runny nose, and other upper respiratory tract symptoms are rare. Dyspnoea may occur one week after disease onset, and severely affected patients rapidly progress to acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, coagulation Among the 95 COVID-19 patients in this study, ground-glass opacities (43.1%) were mostly seen in the early stage imaging presentation and lesions were mainly located at the subpleural region in the lung periphery; this distribution may be due to the fact that virus particles fuse with the alveolar epithelium when they reach the cortical lobules in the lower lungs. This causes injury to the alveolar walls, vascular congestion, the accumulation of exudate in the alveoli, swelling around the lobule, and the simultaneous involvement of multiple adjacent lobules. In the early stage of disease, this mainly presents as interstitial ground-glass opacities. At later stages of disease, the lobules fuse, resulting in an irregular morphology and distribution of lesions that does not follow lung segments, and a fan-like distribution of lesions in subpleural areas [11, 12] . In the progression stage, expansion of the lesion area is typically seen, with frequent involvement of multiple lung segments and lobes (21/34, Journal Pre-proof J o u r n a l P r e -p r o o f 61.8％). Some patients may present with ground-glass opacities in combination with consolidation and grid-like or cord-like shadows (30.5%). This is mainly due to the collapse of alveolar walls, and the replacement of air in the alveoli with Inflammatory exudate, cells, or tissue. The loss of air contrast causes the walls of pulmonary blood vessels and the trachea to become blurry; this often results from interstitial inflammatory thickening [13] . During the progression stage, air bronchograms or vascular thickening can be seen in consolidated areas. The increase in permeability that underlies these changes may be due to pathogen invasion of the bronchiolar and alveolar epithelium, which results in inflammatory cell infiltration and thickening and swelling of the tracheal walls; however, this does not lead to bronchiolar obstruction.

Pathogen invasion of the epithelial cells in the lesion can also result in local vascular congestion and swelling. In the latter stages of disease, lesions may fuse or become partially absorbed [14] . In the severe stage, disease progression is rapid. Ground-glass opacities can be seen with cord-like interstitial thickening, which is considered to be due to the accumulation of cells or exudate; furthermore, the entire lung can be involved with a ‗white lung sign‖.

In this study, a few ground-glass opacities were located at the periphery of [7] World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance. 2020-01-13.https://www.who.int/publications-detail/clinical-management-of-severe-a cute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.

[8] Coronavirus disease 2019 imaging diagnostic guidelines 2020 first edition. Chinese Journal of Radiology, 2020, 54: E001-E001. https://doi.org/10.3760/cma.j.issn.1005-1201.2020.0001.

[9] World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: Interim Guidance [EB/OL]. 2020-01-15. https://www.who.int/internal-publications-detail/surveillance-case-definitions-for-human-infectio n-withnovel-coronavirus-(ncov).

[10] Pan Y, Guan H. Imaging changes in patients with 2019-nCov. European Radiology, 2020, 1-2. https://doi.org/10.1007/s00330-020-06713-z.

[11] Li L, Ren M J, Zhang Y, et al. Lung CT findings of 1 confirmed coronavirus disease 2019 (2019-nCoV) patient (attached with SARS pathology and differential diagnosis). New Medicine, 2020, 30: 4-6. https://doi.org/10.12173/j.issn.1004-5511.2020.01.001.

[12] Tian S, Hu W, Niu L, et al. Pulmonary Pathology of Early Phase SARS-COV-2

Pneumonia. Preprints, 2020. https://doi.org/10.20944/preprints202002.0220.v1.

[13] Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the Journal Pre-proof 

Normal or few abnormal dense shadows 5 9.4% Absence of specific ground-glass opacities or unilateral lung segment patchy shadows 3 5.7%

Local patchy ground-glass opacity 22 41.5% Ground-glass opacity or interlobular septal thickening 4 7.5%

Ground-glass opacity, non-uniform consolidation, and grid-like or cord-like shadows 

the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine

Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

HRCT Imaging Features in Representative Imported Cases of 2019 Novel Coronavirus Pneumonia

Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China

Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion

World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCov) in suspected human cases

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement